Market research
EDT.TO Spectral Medical Inc
TO CAD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 3.15
- Dividend yield
- Not available
- Beta
- 0.21
Profile
Company facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- CA8475771033
- Market cap
- 396M
- P/E ratio
- Not available
- Analyst target
- 3.15
- Dividend yield
- Not available
- Beta
- 0.21
About
About Spectral Medical Inc
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, Russia, and internationally. The company markets Endotoxin Activity Assay, a rapid in-vitro diagnostic test for the detection of components of gram negative; and Polymyxin B-Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops, manufactures, and markets monoclonal and polyclonal antibodies, recombinant cardiac proteins, antibodies, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EDT.TO discussion.
5 years, 5 months ago
Spectral Medical Inc is currently in a long term uptrend where the price is trading 6.8% above its 200 day moving average.
From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 58.7.
Spectral Medical Inc's total revenue sank by 28.3% to $535K since the same quarter in the previous year.
Its net income has dropped by 51.8% to $-2M since the same quarter in the previous year.
Finally, its free cash flow fell by 10.5% to $-2M since the same quarter in the previous year.
Based on the above factors, Spectral Medical Inc gets an overall score of 2/5.